Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760629 | 0.86 | SMN1; SMN2 (0.43) | SCN2ASCN10ASCN5APDE10A | |
| SCHEMBL5759386 | 0.84 | SCN10A (0.45) | SCN2ASCN10ASCN5APDE10A | |
| SCHEMBL5758521 | 0.83 | PDE10A (0.49) | SCN2ANPY5RSCN10ASCN5APDE10A | |
| SCHEMBL5759286 | 0.82 | NPY5R (0.47) | SCN2ANPY5RSCN10ASCN5A | |
| SCHEMBL5760901 | 0.81 | SCN2A (0.44) | SCN2ASCN10ASCN5ACCNB2CDK1 | |
| SCHEMBL5758378 | 0.78 | CNR1 (0.41) | EGFRDPP4 | |
| SCHEMBL5758675 | 0.77 | SCN2A (0.54) | SCN2ATRPV1NPY5RSCN10ACCNB2 | |
| SCHEMBL5756347 | 0.77 | NPY5R (0.47) | SCN2ATRPV1NPY5R | |
| SCHEMBL25303515 | 0.73 | SCN2A (0.55) | SCN2ATRPV1NPY5RSCN10ASCN5A | |
| SCHEMBL25833757 | 0.73 | SCN2A (0.55) | SCN2ATRPV1NPY5RSCN10ACCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | SCN2A 1133/4885TRPV1 619/4885EGFR 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.